IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IDH1
and
IDH2
mutations in lung adenocarcinomas: Evidences of subclonal evolution
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-04-25
DOI
10.1002/cam4.3058
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
- (2019) Bin Fan et al. INVESTIGATIONAL NEW DRUGS
- Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens
- (2019) Li-Hui Tseng et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Non–small cell lung cancers with isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) mutations
- (2018) Laura N. Toth et al. HUMAN PATHOLOGY
- IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer
- (2018) Jiang-jiang Li et al. Molecular Oncology
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
- (2018) Iwona Lugowska et al. Journal of Cancer
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- IDH1 mutation promotes lung cancer cell proliferation through methylation of Fibulin-5
- (2018) Bingdi Yan et al. Open Biology
- Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers
- (2018) Federico De Marchi et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
- (2017) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical mutational profiling of 1006 lung cancers by next generation sequencing
- (2017) Peter B. Illei et al. Oncotarget
- IDH mutations in cancer and progress toward development of targeted therapeutics
- (2016) L. Dang et al. ANNALS OF ONCOLOGY
- Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing
- (2016) Gang Zheng et al. CANCER CYTOPATHOLOGY
- Isocitrate dehydrogenase mutations in myeloid malignancies
- (2016) B C Medeiros et al. LEUKEMIA
- A new functionalIDH2genetic variant is associated with the risk of lung cancer
- (2016) Jiangjiang Li et al. MOLECULAR CARCINOGENESIS
- CDX-2 Expression in Primary Lung Adenocarcinoma
- (2016) Morgan L. Cowan et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers
- (2015) Lisa Haley et al. MODERN PATHOLOGY
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
- (2015) Nicholas McGranahan et al. Science Translational Medicine
- Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies
- (2015) Liang Xia et al. Oncotarget
- Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase.
- (2015) Hongdo Do et al. Oncotarget
- Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing
- (2014) Ming-Tseh Lin et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation
- (2014) Remco J. Molenaar et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Cytosine Deamination Is a Major Cause of Baseline Noise in Next-Generation Sequencing
- (2014) Guoli Chen et al. Molecular Diagnosis & Therapy
- Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Non-Small Cell Lung Cancer
- (2013) N. Sun et al. CLINICAL CANCER RESEARCH
- Cancer Digital Slide Archive: an informatics resource to support integrated in silico analysis of TCGA pathology data
- (2013) David A Gutman et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
- (2012) H. Thorvaldsdottir et al. BRIEFINGS IN BIOINFORMATICS
- Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
- (2012) Benjamin R. Kipp et al. HUMAN PATHOLOGY
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
- (2012) Marco Gerlinger et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
- (2011) M Fernanda Amary et al. JOURNAL OF PATHOLOGY
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
- (2011) D. R. Borger et al. ONCOLOGIST
- IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
- (2010) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Erratum: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2010) Lenny Dang et al. NATURE
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
- (2009) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
- (2009) Marc Sanson et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search